Related Articles
Tolerability and efficacy of pegylated consensus interferon‑α in the treatment of chronic hepatitis C
Interleukin-28B polymorphisms are associated with an early viral response in patients receiving hepatitis C therapy
Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment
MHC class I-related chain B gene polymorphism is associated with virological response to pegylated interferon plus ribavirin therapy in patients with chronic hepatitis C infection
Effect of HCV treatment response on insulin resistance: A systematic review and meta‑analysis Corrigendum in /10.3892/etm.2019.8334